Allscripts
Submitted by admin_alex on Sun, 04/30/2017 - 06:49Pfizer, Inc.
Submitted by admin_alex on Sun, 04/30/2017 - 06:49PricewaterhouseCoopers
Submitted by admin_alex on Sun, 04/30/2017 - 06:49Sonora Quest Laboratories
Submitted by admin_alex on Sun, 04/30/2017 - 06:49Strategic Interests, LLC
Submitted by admin_alex on Sun, 04/30/2017 - 06:49Surescripts
Submitted by admin_alex on Sun, 04/30/2017 - 06:49United Healthcare
Submitted by admin_alex on Sun, 04/30/2017 - 06:49Validic
Submitted by admin_alex on Sun, 04/30/2017 - 06:49The New Medicare Physician Payment Model Under MACRA: Initial Observations – Part 2
In Part 1 of this post, I provided an overview of the new Medicare Quality Payment Program (QPP) proposed in response to the 2015 Medicare Access and CHIP Reauthorization Act (MACRA), which sets out a path to value-based Medicare physician payment. The CMS proposed rule implementing MACRA was released April 27; comments are due June 27. In Part 2, I summarize healthcare IT (HIT) implications of the QPP and provide my initial observation on the proposed rule.
Why EHRs Will Have Different Documentation Requirements for Biosimilar Dispensing, Administration, and Outcomes
While a second biosimilar recently being approved in the United States does not a tsunami make, biosimilars are nonetheless expected to quickly become mainstream. In response, stakeholders are beginning to work on how to make them safe and useful within the parameters of today’s healthcare system because, biosimilars – like biologics – are made from living organisms, which makes them very different from today’s conventional drugs.